R&D Pipeline

R&D Pipeline Pipeline (2021-2030)

Pipeline (2021-2030)

Metabolic - Small molecules (25)

Modality Indication Targets Stage Company Project No. Detail
1 Completion of Preclinical Studies and Phase 2b IND Approval of J2H-1702, a MASH Drug Candidiate
Small molecules MASH 11β-HSD1 Preclinical J2H BIOTECH RS-2026-25503865
2 Development of a novel small-molecule anti-obesity drug based on inhibition of ****
Small molecules Obesity **** Candidate JW Pharmaceutical RS-2025-25455548
3 Development of a ZBP1-Targeting Small Molecule Therapeutic for Alcoholic Liver Disease: Lead Compound Identification Through Inhibition of Inflammatory Cell Death Pathways
Small molecules Hepatic disease ZBP1 Hit UNIST RS-2025-02222987
4 Preclinical development of KARS1-target drug candidate with broad and high efficacy for treatment of MASH (metabolic dysfunction-associated steatohepatitis)
Small molecules MASH KARS1 Preclinical Zymedi RS-2025-02202980
5 Development of candidate compounds as PPARgamma/AMPK dual agonists for treatment of diabetes
Small molecules Diabetes PPARr, AMPK Candidate dalimbiotech RS-2025-02172988
6 Development of Therapeutics for Liver Fibrosis through the Discovery of Collagen Inhibitors
Small molecules Liver fibrosis Serpin Family Candidate Daewoong Pharmaceutical RS-2024-00463096
7 Lead compound generation of DYRK1B inhibitor for NASH treatment
Small molecules Liver fibrosis DYRK1B Lead Therasid Bioscience Inc. RS-2023-00283399
8 Discovery of lead compounds based on increase of lipolysis and energy expenditure to treat obesity
Small molecules Obesity ALK7 Lead Gachon University RS-2023-00282576
9 Development of KARS1-target drug candidate with broad and high efficacy for treatment of NASH (non-alcoholic steatohepatitis)
Small molecules NASH KARS1 Candidate Zymedi RS-2023-00218823
10 Development of STK25 inhibitor for treatment of nonalcoholic steatohepatitis
Small molecules NASH STK25 Lead Korea Research Institute of Chemical Technology RS-2023-00218351
11 A First-in-Class Treatment for Non-alcoholic Steatohepatitis
Small molecules NASH HTR2A Phase 1 JD BIOSCIENCE INC. RS-2023-00218035
12 Drug development for Duchenne muscular dystrophy by increasing mRNA stability
Small molecules Duchenne muscular dystrophy NMD Lead RiboTech HN22C0723
13 Discovery of dual A2A adeosine receptor agonist/A3 adenosine antagonist as anti-obesity drug
Small molecules Obesity A2AAR, A3AR Lead Seoul National University HN22C0687
14 LPA1 antagonist AMS-III-1086; Pre-clinical study for liver fibrosis treatment
Small molecules Liver fibrosis LPAR1 Preclinical am SCIENCES HN22C0594
15 Treatment of NASH using autophagy enhancer ameliorateing organelle stress
Small molecules NASH TFEB Hit LysoTech HN22C0278
16 Development of peripheral cannabinoid 1 receptor antagonists targeting diabetes and metabolic disease using AI/CADD-based technology
Small molecules Diabetes CB1R Lead Sungkyunkwan University HN22C0203
17 Developing treatment for metabolic disease targeting PPARγ phosphorylation based on adipocyte remodeling
Small molecules Diabetes, Obesity PPARγ S273 Hit Korea Research Institute of Bioscience and Biotechnology HN22C0120
18 Discovery of hit and lead compounds based on oral IP6 kinase inhibition to treat obesity
Small molecules Obesity IP6K Hit Korea Advanced Institute of Science and Technology HN21C1265
19 JP-2266: Novel SGLT1/2 dual inhibitor for the treatment of diabetes mellitus
Small molecules Diabetes SGLT1/2 Phase 1 Jeil Pharmaceutical Co., Ltd. HN21C0675
20 Development of a PPAR/AMPK dual agonist for treatment of diabetes and metabolic syndrome
Small molecules Diabetes PPARγ, AMPA Lead Seoul National University Hospital HN21C0497
21 Development of PAK4 inhibitor as anti-diabetes drug
Small molecules Diabetes PAK4 Hit Jeonbuk National University HN21C0447
22 Development of Lead compounds as a Deubiquitinase USP1 Inhibitor for Non-Alcoholic Fat Liver Diseases Therapy
Small molecules NASH USP1 Lead Yonsei University HN21C0153
23 Development of lead compounds as a sphingomyelin synthase 1 inhibitor to reduce the hepatocyte lipotoxicity for the treatment of liver cirrhosis
Small molecules Cirrhosis SMS1 Hit Seoul National University HN21C1150
24 Development of HIT compounds of MLKL inhibitors for treatment of nonalcoholic fatty liver disease
Small molecules NASH MLKL Hit Hanyang University HN21C1149
25 Development of lead for intestinal glucotonic therapeutics based on atypical PKC activation for treatment of metabolic syndrome
Small molecules Diabetes, Obesity Atypical PKC Hit Yonsei University HN21C1008
BACK